Payment overview · 2025
General Payments
$498.83
29 reported records · 7 companies
Healthcare provider profile · identity verified
Jackie D Shorter, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · PINEVILLE, WV · NPI 1871676874
Verified facts
What the public records show
CMS Open Payments records show Jackie D Shorter, PAC received $498.83 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.45 | 41.8% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.20 | 28.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.65 | 7.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.92 | 6.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.59 | 6.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.32 | 5.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.70 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.83 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.66 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.66 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.45 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.45 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.65 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 387 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 81 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 338 | 74 |
| Omeprazole | Omeprazole | 295 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 67 |
| Lisinopril | Lisinopril | 250 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 72 |
| Potassium Chloride | Potassium Chloride | 233 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 73 |
| Furosemide | Furosemide | 218 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 64 |
| Montelukast Sodium | Montelukast Sodium | 198 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 55 |
| Famotidine | Famotidine | 181 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 66 |
| Prednisone | Prednisone | 168 | 132 |
| Tramadol Hcl | Tramadol Hcl | 160 | 40 |
| Lorazepam | Lorazepam | 139 | 36 |
| Cefdinir | Cefdinir | 138 | 117 |
| Glipizide Er | Glipizide | 135 | 41 |
| Ibuprofen | Ibuprofen | 127 | 55 |
| Simvastatin | Simvastatin | 123 | 30 |
| Meloxicam | Meloxicam | 121 | 38 |
| Metformin Hcl | Metformin Hcl | 115 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 31 |
| Ondansetron Odt | Ondansetron | 111 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 18 |
| Fluconazole | Fluconazole | 91 | 54 |
| Diazepam | Diazepam | 90 | 18 |
| Ozempic | Semaglutide | 88 | 22 |
| Valsartan | Valsartan | 86 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 27 |
| Trazodone Hcl | Trazodone Hcl | 78 | 17 |
| Pregabalin | Pregabalin | 77 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 30 |
| Ibu | Ibuprofen | 75 | 26 |
| Eliquis | Apixaban | 74 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 20 |
| Metformin Hcl Er | Metformin Hcl | 67 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 18 |
| Nystatin | Nystatin | 65 | 26 |
| Temazepam | Temazepam | 64 | 13 |
| Levofloxacin | Levofloxacin | 63 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 42 |
| Lactulose | Lactulose | 61 | 23 |
| Mupirocin | Mupirocin | 61 | 43 |
| Azithromycin | Azithromycin | 59 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 52 |
| Promethazine Hcl | Promethazine Hcl | 56 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 18 |
| Bupropion Xl | Bupropion Hcl | 54 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 53 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Cephalexin | Cephalexin | 49 | 44 |
| Glimepiride | Glimepiride | 49 | 13 |
| Losartan Potassium | Losartan Potassium | 49 | 25 |
| Ezetimibe | Ezetimibe | 48 | 12 |
| Meclizine Hcl | Meclizine Hcl | 48 | 25 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 20 |
| Allopurinol | Allopurinol | 45 | 13 |
| Baclofen | Baclofen | 45 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 11 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Torsemide | Torsemide | 42 | 13 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 33 |
| Atenolol | Atenolol | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 16 |
| Methocarbamol | Methocarbamol | 36 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 12 |
| Bumetanide | Bumetanide | 34 | 11 |
| Fenofibrate | Fenofibrate | 34 | 11 |
| Sucralfate | Sucralfate | 34 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 27 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | 12 |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 25 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 12 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.83 · 29 records | Novo Nordisk Inc | AIRSUPRA, FREESTYLE LIBRE 2, LINZESS, Ohtuvayre, Ozempic, PAXLOVID, PROCLAIM, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error